Pfizer recently agreed to hold off raising prices for certain drugs after Trump criticized the company and said it should be “ashamed” of the move. (Photo: Andrew Harrer/Bloomberg)

Drugmakers will likely get rid of secret discounts to middlemen that have become a focus of the U.S. drug-cost debate, Pfizer Inc. Chief Executive Officer Ian Read predicted Tuesday.

“We’re going to go to a marketplace where we don’t have rebates,” Read told analysts while discussing the company’s second-quarter financial results.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.